Premium
Detection of Angiotensin II type I‐receptor antibodies in transplant glomerulopathy
Author(s) -
Bussolino Stefania,
Dolla Caterina,
Ariaudo Claudia,
Civiletti Federica,
Messina Maria,
Mella Alberto,
Caorsi Cristiana,
Amoroso Antonio,
Barreca Antonella,
Papotti Mauro,
Giunti Sara,
Fop Fabrizio,
Biancone Luigi
Publication year - 2018
Publication title -
clinical transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 76
eISSN - 1399-0012
pISSN - 0902-0063
DOI - 10.1111/ctr.13407
Subject(s) - medicine , gastroenterology , antibody , titer , biopsy , angiotensin ii , immunology , receptor
Abstract Background Transplant glomerulopathy (TG) is an important cause of late graft loss. The role of angiotensin type 1‐receptor antibodies (AT 1 R‐Ab) in TG is not known. Methods All the TG cases (N = 137) between January 2007 and December 2014 (N = 1410) were analyzed. Donor‐specific anti‐HLA antibodies (DSA) at the time of biopsy and AT 1 R‐Ab IgG (positive, >17 UI/mL; “at risk,” 10‐17 UI/mL; negative, <10 UI/mL) in pre‐transplant sera (PT‐Ab) and at biopsy time (BT‐Ab) were studied. Results AT 1 R‐PT‐Ab + and AT 1 R‐BT‐Ab + patients were 16.5% (51.5% “at risk”) and 11.5% (27.4% “at risk”), respectively. Clinical correlations were found between AT 1 R‐Ab and HCV infection, number of transplants, and age. Considering Banff scores, ptc was higher in DSA + patients vs AT 1 R‐PT‐Ab + ( P = 0.002) or AT 1 R‐BT‐Ab + ( P = 0.001) without differences in g and chronicity score (ci + ct); cg showed lower scores in DSA + patients vs AT 1 R‐BT‐Ab + ( P = 0.001). Graft survival was not influenced by the presence of AT 1 R‐Ab, AT1‐R‐Ab titer or MFI, but we observed a longer graft survival in patients with both AT 1 R‐BT‐Ab + or “at risk” and DSA + vs patients positive only for DSA ( P = 0.02), for AT 1 R‐BT‐Ab ( P = 0.019) or AT 1 R‐BT‐Ab “at risk” ( P = 0.039). Conclusion AT 1 R‐Ab showed no independent prognostic role in TG in this pilot analysis.